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ABSTRACT

The research that we have conducted has allowed us to discover
that the amino acids, methionine (Met) and N-acetyl methionine (NAcMet), will react in a 1:1 and 1:2 molar ratio with platinum complexes
containing bulky diamine ligands. Previous research has allowed us to
gain a plethora of information on the experimentation and results of
specific bulky diamine ligands such as N,N,N',N'tetramethylethylenediamine and N,N-diethylethylenediamine. In the
current study, we have investigated the bulky diamine ligand of N,Ndimethylethylenediamine, or Me2en. With our focus on the bulk of the
Me2en ligand, we have been able to synthesize a platinum complex in
Pt(Me2en)Cl2 and react it with Met and N-AcMet. Through analysis using
NMR spectroscopy and LC/MS, we have been able to observe the
formation of a S,O-chelate formation in the reaction of the platinum
complex with N-AcMet. This implies that a second methionine is not able
to coordinate to the position that is cis to the bulk.

Keywords: Cisplatin, Methionine, Nuclear Magnetic Resonance, Ligand,
Chelate
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CHAPTER 1

INTRODUCTION

As time has progressed, a vast amount of diseases and illnesses
have become apparent in society. However, with time, a plethora of
treatments and scientific advances have made way into the
pharmaceutical industry to counteract these diseases and illnesses. One
of the most significant diseases in the world today is cancer. There are
many different forms of cancer that specialize in attacking different
tissues and organs of the body. These different forms of cancer tend to
have such diverse symptoms on the body, with the most significant being
death. These devastating symptoms have led to many scientists
experimenting with a wide array of anticancer treatments ranging from
new radiation and chemotherapy techniques to development of novel
anticancer drugs. These new developments eventually led way to
research surrounding platinum (II) compounds and their affect on
suppressing cancer. This breakthrough in platinum chemistry
established the foundation for this research project concerning the
reaction of bulky platinum (II) complex’s with amino acids.
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One of the most significant anticancer drugs used today is a
platinum based drug known as cisplatinum, cisplatin, or cisdiamminedichloroplatinum. The discovery of cisplatin and all of its
anticancer attributes was a great breakthrough in the field of oncology.
Not only did cisplatin revolutionize how cancer could be treated, but it
also led to the development and research of other derivatives of platinum
compounds and their significance on anticancer activity. Oxaliplatin and
carboplatin were two platinum compounds discovered from cisplatin that
have been determined to act as anticancer agents.

H3N

Pt

Cl

NH3
Cl

Figure 1. Illustration of cisplatinum, cisplatin, or cis-diamminedichloroplatinum.

Cisplatin is an incomparable drug in that it is not complex in
structure, yet has the ability to target and fight certain cancers in the
body. Structurally speaking, cisplatin, or Pt(NH3)2Cl2, consists of two
ammine ligands and two chloride ligands in ideal biological conditions as
depicted in Figure 1. It maintains a square planar geometry1. Platinum
(II) tends to have a high affinity for nitrogen and sulfur ligands, which are
commonly found in proteins and nucleotides in DNA2; this is a result of
platinum being known as a “soft” acid and bonding strongly as described
by the Hard Soft Acid Base theory5,6. This platinum complex can be
found in two conformations: cis, the commonly used anticancer drug,
2

and trans, the inactive form5,6. These features of cisplatin allow it to
function flawlessly in the body.
Originally the compound has been known since 1845, but its
anticancer activity was not discovered until 19701. Cisplatin, formely
known as Peyrone’s chloride, was synthesized by Michael Peyrone in
18451,8. The drug’s activity was discovered by Dr. Barnett Rosenberg at
Michigan State University in which he was able to experiment with how
platinum complexes could lead to inhibition of cell proliferation1,5,6.
Ironically, Rosenberg was focusing on bacterial growth’s effects from
electric fields using platinum electrodes; this eventually led to the origin
of cisplatin1. Rosenberg was then able to test cisplatin on tumors in
mice, which showed the effectiveness of the drug1. Cisplatin was
eventually approved by the United States Food and Drug Administration
and became licensed to Bristol-Myers Squibb in 19777. It is the main
component in the drug Platinol® and its derivative, carboplatin, is known
as Paraplatin®7. The purpose of cisplatin was to be used in
chemotherapy in order to target ovarian, testicular, stomach, lung, and
bladder cancers5,6. The administering of cisplatin for testicular cancer
treatments has led to a dramatic increase in survival rate from 10% to
80%7.
Not only is cisplatin, and its derivatives, notable for its ability to be
an ideal treatment for most cancers, but it is also one of a few cancer
drugs based from inorganic complexes; most cancer drugs used today
3

are complex in structure due to the compilation of many organic
molecules. The structure of cisplatin causes it to alter the repair
mechanism of the cell by binding to the DNA and eventually leading to
the suppression of cancer cells from proliferating1,2. Once the drug has
entered the cell, it undergoes hydrolysis in which a charged platinum
complex forms while one of the chlorine ligands is displaced due to it
being replaced by a water molecule1,2. The platinum complex is
coordinated to DNA. The platinum complex eventually coordinates to a
second nucleotide, resulting because of further hydrolysis and
displacement of the second chloride ligand1,2. This newly formed adduct
eventually leads to a kink in the DNA helix1,2. The formed complexes
have a tendency to react with both protein and DNA1,2.
Cisplatin’s main component, platinum, tends to have a great
affinity for binding sites on proteins containing sulfur molecules. Sulfur
atoms are only available in two kinds of amino acid residues, one being
cysteine, and the other being of interest, methionine. The sulfur on the
methionine contains a slightly partial positive charge and is available as
a thioether. The interaction between methionine and cisplatin can lead
to the formation of monodentate and bidentate compounds.

O

S

O
+

NH 3

Figure 2. Depiction of the amino acid, methionine.
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The proposed research project focuses on the Pt(Me2en)Cl2
complex, where the Me2en ligand is N,N-dimethyethylenediamine, and its
interactions with L-Methionine (Met) and N-Acetyl Methionine (N-AcMet).
It was noted that Met and N-AcMet reacts in a 1:1 and 1:2 molar ratio
with platinum complexes containing bulky diamine ligands. Previous
research has allowed us to gain a plethora of information on the
experimentation and results of specific bulky diamine ligands such as
N,N,N',N'-tetramethylethylenediamine (Me4en) and N,Ndiethylethylenediamine (Et2en)3,4. The current Me2en ligand does appear
to have sufficient bulk to prevent coordination of a second Met or NAcMet to the coordination position cis to the bulk of the methyl groups.
The sulfur atom of the first methionine is able to coordinate to the trans
position, however, a sufficient amount of bulk is still surrounding the cis
position in relation to the methyl groups on the ligand. This leads to the
oxygen of the first methioine coordinating to the cis position and forming
a S,O- chelate instead of a sulfur atom of a second methionine
coordinating to that positions. The displacement of the Me2en ligand
occurred and the formation of a mono product was detected through
NMR spectroscopy.

N

H2 N
Pt
Cl

NH23

N

Cl

Figure 3. Structure of Pt(Me2en)Cl2 and Me2en ligand.
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This research allows an in-depth perspective of the reaction of bulky
platinum complexes with L-Methionine and N-Acetyl Methionine and how
this data can lead to a better understanding of cleavage reactions
involved in proteins3,4.
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CHAPTER 2

METHODOLOGY

Synthesis of Pt(Me2en)Cl2:
In order to properly exhibit the formation of any product through the
coordination of a peptide, the Pt(Me2en)Cl2 complex needed to be
synthesized. Potassium tetrachloroplatinate was dissolved in H2O.
Dimethylethylenediamine was combined with methanol. This solution
was then added drop-wise to the previous solution. The combined
solution stirred for 24 hours (developed a “peach” color). Upon
completion of stirring, the solution was placed on the rotary evaporator
in order for the sample to be cooled and a product be precipitated; this
process yielded a final product of Pt(Me2en)Cl2.
Reaction of Pt(Me2en)Cl2 with L-Methionine and N-Acetyl
Methionine:
The Pt(Me2en)Cl2 complex needed to be reacted with various proportions
of amino acids and monitored for periods of times to observe any
displacement of the Me2en ligand and formation of any product
complexes. Approximately 3.5 mg of the platinum complex was dissolved
in 1.0 mL of deuterium oxide (D2O) and reacted with L-Methionine and
N-acetyl methionine (2 and 4 mg); these samples were adjusted to a pH
7

of 4. This allowed us to compare the reactions at a 1:1 and 1:2 molar
ratio and monitor the samples at various time intervals through NMR
spectroscopy.
NMR Spectroscopy:
The reactions of the platinum complexes with proportions of the peptides
were analyzed using 1H NMR spectroscopy. This data was attained on a
JOEL Eclipse 500MHz NMR instrument. Through NMR spectroscopy and
analysis, we can determine when there may be a displacement of the
Me2en ligand, when the major products are forming, and find any
correlation between the different ratios of the samples.
LC/MS
A 5mM concentration of the platinum complex was reacted with a 10mM
concentration of Met and N-AcMet and then analyzed by liquid
chromatography/ mass spectrometry. The data was attained on a Varian
LC/MS 500 Ion Trap. This instrumentation helps in distinguishing
various compounds from each other using a mass-to-charge ratio; this is
useful for this research in detecting any possible chelate formations.
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CHAPTER 3

RESULTS

Based on the intensity and shift of the peak signals in relation to
the other signals, we can determine the presence of any product
complexes, as well as the possible structure/coordination of the product.
It can be inferred that displacement of the bulky diamine ligand typically
will only occur when both coordination positions trans to the diamine
ligand are occupied by sulfur atoms that originated from the amino
acids.
However, upon conducting experiments utilizing LC/MS, the
experiment involving the reaction of the platinum complex with N-AcMet
suggested that a sulfur atom coordinated to the trans position in relation
to the methyl groups on the ligand, and the oxygen atom on the same
methionine coordinated to the cis position—this formed a S,O chelate.
This was determined from the LC/MS by a peak at 473.3 mass-to-charge
ratio.
Previous studies with Pt(Me4en)(NO3)2 complexes have indicated
that only one Met or N-AcMet could possibly coordinate because of steric
clashes3,4. Together, these results have been able to suggest that two
9

methyl groups on one amine nitrogen are sufficient to prevent
coordination of a sulfur atom from a second methionine.

N

H2N
Pt

O
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O

Figure 4. Structure of Pt(Me2en)(NAcMet-S,O).
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Reaction of Pt(Me2en)Cl2 with L-Methionine and N-Acetyl Methionine
[1:1 ratio]:
Pt(Me2en)Cl2 was dissolved in 1mL of deuterium oxide and reacted with
4mg of L-Methionine. This reaction was observed by NMR analysis and
data was collected at time intervals of 1, 4, and 24 hours.

a.
Unreacted
Methionine

b.
Mono
Product

c.

3.4

2.4

Figure 5. Reaction of Methionine and Pt(Me2en)Cl2 at a 1:1 molar ratio; monitored at (a)
1 hr (b) 4 hrs (c) 24 hrs.
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Pt(Me2en)Cl2 was dissolved in 1mL of deuterium oxide and reacted with
4mg of N-Acetyl Methionine. This reaction was observed by NMR
analysis and data was collected at time intervals of 1, 4, and 24 hours.

Unreacted
N-Acetyl
Methionine

a.

b.

Mono
Product

c.

Me2en
ligand

3.4

2.4

Figure 6. Reaction of N-Acetyl Methionine with Pt(Me2en)Cl2 at a 1:1 molar ratio;
monitored at (a) 1 hr (b) 4 hrs (c) 24 hrs.
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Reaction of Pt(Me2en)Cl2 with L-Methionine and N-Acetyl Methionine
[1:2 ratio]:
Pt(Me2en)Cl2 was dissolved in 1mL of deuterium oxide and reacted with
2mg of L-Methionine. This reaction was observed by NMR analysis and
data was collected at time intervals of 1, 4, and 24 hours.
a.

Unreacted
Methionine

b.
Mono
Product

c.

Me2en
ligand

3.4

2.4

Figure 7. Reaction of L-Methionine with Pt(Me2en)Cl2 at 2:1 ratio; monitored at (a) 1hr
(b) 4hrs (c) 24 hrs.
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Pt(Me2en)Cl2 was dissolved in 1mL of deuterium oxide and reacted with
2mg of N-Acetyl Methionine. This reaction was observed by NMR
analysis and data was collected at time intervals of 1, 4, and 24 hours.
Unreacted
N-Acetyl
Methionine

a.

b.

c.
Mono
Product

Me2en
ligand

3.4

2.4

Figure 8. Reaction of N-Acetyl Methionine with Pt(Me2en)Cl2 at a 2:1 ratio; monitored at
(a)1hr (b) 4hrs (c) 24 hrs.
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Peak signals at ~3.0ppm and ~3.4ppm correspond to displacement of the
Me2en ligand. This is attained through the coordination of the
methionine.
Reaction of 5mM Pt(Me2en)Cl2 with 10mM N-AcMet
AcMet (LC/MS):

Pt(Me2en)(NAcMet-S,O)

Figure 9. Mass spectrometry data of N-Acetyl
Acetyl Methionine with Pt(Me2en)Cl2 .
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CHAPTER 4

DISCUSSION

It was suspected that due to the sufficient bulk of the Me2en
ligand, there would not be coordination of a second L-Methionine or NAcetyl Methionine to the platinum complex. Past research has shown
that various bulky ligands, such as Et2en and Me4en, do not allow the
sulfur atom of a second methionine to coordinate to the platinum
complex3-5. The research surrounding these other bulky ligands were
able to conclude that only one methionine would coordinate to the
platinum complexes and result in the formation of a S,O-chelate. Hence,
the objective of this research project was to determine the significance of
bulkiness of this ligand and how the bulk on the platinum complex
relates to the binding of methionine’s found in proteins in the body. This
research project, implementing NMR spectroscopy and LC/MS, allowed
the retrieval of significant data leading towards the probability of the
formation of a S,O-chelate.
Past research has proven that the sulfur atom of methionine will
react rapidly with the platinum. So, it could be inferred that the sulfur
atom would react at either the cis or trans coordination positions relative
16

to the nitrogen atom containing the two methyl groups. The sulfur atom
has the greatest probability of coordinating to the trans position. The
bulk of the Me2en ligand, and specifically the bulky nitrogen atom, are
showing that the sulfur cannot be in the cis position, and leads to the
formation of [Pt(Me2en)(N-AcMet-S,O)]. This chelate formation was
verified by a peak at 473.3 mass-to-charge ratio under LC/MS analysis,
as well as a doublet of doublets formation at ~5.4ppm through NMR
spectroscopy. Research performed on the Et2en and Me4en ligand
reported that the sulfur atom from methionine will coordinate to the
trans position relative to the bulky nitrogen atom as well. However, that
research also reported that the bulk of those ligands caused no
coordination of another sulfur atom from methionine at the cis position.
This research on the Me2en ligand shows that this bulk still allows
coordination of the carboxyl oxygen of N-Acetyl Methionine to the cis
position, eventually resulting in a S,O-chelate. It is also to be noted that
previous studies showed the formation of S,O-chelates involving the
coordination of amino acids to platinum complexes.
The present study allowed the utilization of a platinum complex
containing a non-C2-symmetrical Me2en ligand to determine if excessive
bulk on one of the two nitrogens of the diamine ligand could inhibit
coordination of the second methionine to the platinum complex and/or
greatly affect the type of chelate that would form. This research helps to
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understand to the basis of cleavage reactions found in proteins during
the reaction of platinum complexes with methionine.

18

CHAPTER 5

FUTURE WORK

Further research will allow us to focus on the characterization of
the products using NMR spectroscopy, high pressure liquid
chromatography (HPLC), and mass spectrometry. Currently, more
analysis is being done using 2D NMR and various kinetic NMR
experiments. It is also essential to characterize the products formed in
the reactions of Pt(Me2en)Cl2 with 5’-GMP (guanosine monophoshpate).
Lastly, focus on the rates of reactions and molecular mechanics of
Pt(Me2en)Cl2 with methionine and guanine targets is crucial in the
continuation of this research.
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